Tocilizumab in refractory pretibial myxedema: new therapeutic insights
JCEM Case Reports · 16.10.2026 · 4 (12)
DOI: 10.1210/jcemcr/luag249 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 22.10.2026. Verfasst von Silvia Corrias und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, CA, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pretibial myxedema (PTM) is a rare extrathyroidal manifestation of Graves disease, often associated with Graves orbitopathy (GO). Tocilizumab, an interleukin-6 receptor inhibitor, is effective in refractory GO, but its role in PTM is unclear. We report the case of a 72-year-old woman with longstanding Graves disease who developed glucocorticoid-refractory GO and diffuse glucocorticoid-refractory PTM. Tocilizumab (8 mg/kg intravenously every 4 weeks) was initiated as second-line treatment of moderate to severe active GO. After 6 infusions, the patient experienced a significant improvement in both activity and severity of GO, while PTM showed near-complete resolution of edema and skin induration. No adverse events were recorded. Our findings suggest that interleukin-6 receptor inhibition with tocilizumab may represent a novel therapeutic option for refractory thyroid dermopathy, particularly in the setting of concomitant GO.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, CA, Italy.
- Ophthalmology Unit, Department of Surgical Sciences, University of Cagliari, 09042 Monserrato, CA, Italy.
ORCID-Profile: Francesco Boi, Giulia Lanzolla
Zitieren
APA
Corrias, S., Arba, A., Lixi, F., Giannaccare, G., Boi, F., & Lanzolla, G. (2026). Tocilizumab in refractory pretibial myxedema: new therapeutic insights. JCEM Case Reports, 4(12). https://doi.org/10.1210/jcemcr/luag249
Vancouver
Corrias S, Arba A, Lixi F, Giannaccare G, Boi F, Lanzolla G. Tocilizumab in refractory pretibial myxedema: new therapeutic insights. JCEM Case Reports. 2026;4(12). doi:10.1210/jcemcr/luag249
BibTeX
@article{Corrias2026,
author = {Corrias, Silvia and Arba, Aurora and Lixi, Filippo and Giannaccare, Giuseppe and Boi, Francesco and Lanzolla, Giulia},
title = {Tocilizumab in refractory pretibial myxedema: new therapeutic insights},
journal = {JCEM Case Reports},
year = {2026},
volume = {4},
number = {12},
doi = {10.1210/jcemcr/luag249}
}
EUVIMED